{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T20:25:10Z","timestamp":1792182310938,"version":"4.4.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Schizophrenia Research"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.schres.2018.03.006","type":"journal-article","created":{"date-parts":[[2018,3,18]],"date-time":"2018-03-18T12:46:40Z","timestamp":1521377200000},"page":"17-30","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":73,"special_numbering":"C","title":["Clozapine-induced cardiomyopathy and myocarditis monitoring: A systematic review"],"prefix":"10.1016","volume":"199","author":[{"given":"Kristen N.","family":"Knoph","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Robert J.","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian A.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn M.","family":"Schak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda C.","family":"Owen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan R.","family":"Leloux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mayur","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan G.","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.schres.2018.03.006_bb0005","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1177\/070674370304801107","article-title":"From chlorpromazine to clozapine: antipsychotic adverse effects and the clinician's dilemma","volume":"48","author":"Abidi","year":"2003","journal-title":"Can. J. Psychiatr."},{"issue":"2","key":"10.1016\/j.schres.2018.03.006_bb0010","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ijcard.2014.07.103","article-title":"A systematic review of clozapine induced cardiomyopathy","volume":"176","author":"Alawami","year":"2014","journal-title":"Int. J. Cardiol."},{"issue":"11","key":"10.1016\/j.schres.2018.03.006_bb0015","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1177\/0004867415585584","article-title":"Heterogeneity of clozapine-associated myocarditis: An opportunity for novel preventing strategies","volume":"49","author":"Baptista","year":"2015","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.schres.2018.03.006_bb0020","first-page":"352","article-title":"Clozapine-induced myocarditis in observational cross-sectional and follow-up evaluations: comparison with other antipsychotics in naturalistic settings","volume":"57","author":"Baptista","year":"2016","journal-title":"Invest Cl\u00edn."},{"issue":"2","key":"10.1016\/j.schres.2018.03.006_bb0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2165\/00023210-200721020-00003","article-title":"Monitoring the safe use of clozapine: a consensus view from Victoria, Australia","volume":"21","author":"Berk","year":"2007","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.schres.2018.03.006_bb0030","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s40266-013-0144-2","article-title":"Adverse effects of clozapine in older patients: epidemiology, prevention and management","volume":"31","author":"Bishara","year":"2014","journal-title":"Drugs Aging"},{"issue":"3","key":"10.1016\/j.schres.2018.03.006_bb0035","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00002018-200023030-00004","article-title":"Cardiovascular adverse effects of antipsychotic drugs","volume":"23","author":"Buckley","year":"2000","journal-title":"Drug Saf."},{"issue":"1","key":"10.1016\/j.schres.2018.03.006_bb0040","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2013-000030","article-title":"Asymptomatic left ventricular dysfunction with long-term clozapine treatment for schizophrenia: a multicenter cross-sectional cohort study","volume":"1","author":"Chow","year":"2014","journal-title":"Open Heart"},{"issue":"3","key":"10.1016\/j.schres.2018.03.006_bb0045","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3371\/1935-1232.10.3.163","article-title":"Guide to the management of clozapine-related tolerability and safety concerns","volume":"10","author":"Citrome","year":"2016","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"key":"10.1016\/j.schres.2018.03.006_bb0050","unstructured":"Clozapine [package insert]. Morgantown (WV): Mylan Pharmaceuticals; 2017."},{"issue":"10","key":"10.1016\/j.schres.2018.03.006_bb0055","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.4088\/JCP.11r06977","article-title":"Beyond white blood cell monitoring: screening in the initial phase of clozapine therapy","volume":"73","author":"Cohen","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.schres.2018.03.006_bb0060","first-page":"9","article-title":"Myocarditis with antipsychotics: recent cases with clozapine","volume":"19","author":"Committee on Safety in Medicines","year":"1993","journal-title":"Curr. Probl. Pharmacovigilance"},{"issue":"6","key":"10.1016\/j.schres.2018.03.006_bb0065","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/j.psym.2015.07.002","article-title":"Clozapine-induced myocarditis: prevention and considerations in rechallenge","volume":"56","author":"Cook","year":"2015","journal-title":"Psychosomatics"},{"issue":"7296","key":"10.1016\/j.schres.2018.03.006_bb0070","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1136\/bmj.322.7296.1207","article-title":"Antipsychotic drugs and heart muscle disorder in international pharmacovigilance: data mining study","volume":"322","author":"Coulter","year":"2001","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.schres.2018.03.006_bb0075","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1097\/YIC.0000000000000085","article-title":"Impairment of left ventricular function early in treatment with clozapine: a preliminary study","volume":"30","author":"Curto","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"issue":"7","key":"10.1016\/j.schres.2018.03.006_bb0080","doi-asserted-by":"crossref","DOI":"10.1007\/s11920-016-0704-3","article-title":"Systematic review of clozapine cardiotoxicity","volume":"18","author":"Curto","year":"2016","journal-title":"Curr. Psychiatry Rep."},{"issue":"1","key":"10.1016\/j.schres.2018.03.006_bb0085","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2174\/157488612800492681","article-title":"Update on the adverse effects of clozapine: focus on myocarditis","volume":"7","author":"De Berardis","year":"2012","journal-title":"Curr. Drug Saf."},{"issue":"4","key":"10.1016\/j.schres.2018.03.006_bb0090","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/acps.12421","article-title":"Titrating clozapine amidst recommendations proposing high myocarditis risk and rapid titrations","volume":"132","author":"de Leon","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"issue":"5","key":"10.1016\/j.schres.2018.03.006_bb0095","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1080\/j.1440-1614.2000.0822n.x","article-title":"Myocarditis associated with clozapine treatment","volume":"34","author":"Degner","year":"2000","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"9206","key":"10.1016\/j.schres.2018.03.006_bb0100","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/S0140-6736(00)00035-0","article-title":"Clozapine and sudden death","volume":"355","author":"Devarajan","year":"2000","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.schres.2018.03.006_bb0105","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1177\/0004867412449062","article-title":"Clozapine-induced myocarditis and baseline echocardiograms","volume":"46","author":"Ellis","year":"2012","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.schres.2018.03.006_bb0110","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s00414-004-0464-1","article-title":"Sudden cardiac death due to hypersensitivity myocarditis during clozapine treatment","volume":"118","author":"Fineschi","year":"2004","journal-title":"Int. J. Legal Med."},{"issue":"4","key":"10.1016\/j.schres.2018.03.006_bb0115","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/acps.12425","article-title":"Clozapine-induced myocarditis: prescribe safely but do prescribe","volume":"132","author":"Freudenreich","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"issue":"5","key":"10.1016\/j.schres.2018.03.006_bb0120","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1517\/14740338.7.5.525","article-title":"The safety of clozapine in the elderly","volume":"7","author":"Gareri","year":"2008","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.schres.2018.03.006_bb0125","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00002018-200730010-00005","article-title":"Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993\u20132003","volume":"30","author":"Haas","year":"2007","journal-title":"Drug Saf."},{"issue":"4","key":"10.1016\/j.schres.2018.03.006_bb0130","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1097\/00004714-200108000-00005","article-title":"Myocarditis related to clozapine treatment","volume":"21","author":"Hagg","year":"2001","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.schres.2018.03.006_bb0135","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3371\/CSRP.HIFR.01062013","article-title":"Clozapine: key discussion points for prescribers","volume":"6","author":"Hill","year":"2013","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"issue":"1283","key":"10.1016\/j.schres.2018.03.006_bb0140","first-page":"68","article-title":"Clozapine and myocarditis: a case series from the New Zealand Intensive Medicines Monitoring Programme","volume":"121","author":"Hill","year":"2008","journal-title":"N. Z. Med. J."},{"issue":"2","key":"10.1016\/j.schres.2018.03.006_bb0145","first-page":"114","article-title":"Clozapine is underutilized","volume":"24","author":"Kane","year":"2012","journal-title":"Shanghai Arch Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2018.03.006_bb0150","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.schres.2008.10.020","article-title":"Cardiac-related findings at autopsy in people with severe mental illness treated with clozapine or risperidone","volume":"107","author":"Kelly","year":"2009","journal-title":"Schizophr. Res."},{"issue":"2","key":"10.1016\/j.schres.2018.03.006_bb0155","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1176\/appi.ps.201700162","article-title":"Addressing Barriers to Clozapine Underutilization: A National Effort","volume":"69","author":"Kelly","year":"2018","journal-title":"Psychiatr. Serv."},{"key":"10.1016\/j.schres.2018.03.006_bb0160","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.ijcard.2017.03.013","article-title":"Clozapine and incidence of myocarditis and sudden death: long term Australian experience","volume":"238","author":"Khan","year":"2017","journal-title":"Int. J. Cardiol."},{"issue":"1","key":"10.1016\/j.schres.2018.03.006_bb0165","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/1039856212465777","article-title":"Monitoring of long-term cardiac complications in patients receiving clozapine","volume":"21","author":"Kidd","year":"2013","journal-title":"Australas. Psychiatry"},{"issue":"9193","key":"10.1016\/j.schres.2018.03.006_bb0170","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/S0140-6736(99)10385-4","article-title":"Myocarditis and cardiomyopathy associated with clozapine","volume":"354","author":"Kilian","year":"1999","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.schres.2018.03.006_bb0175","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1080\/14740338.2017.1257604","article-title":"Exploiting heterogeneous publicly available data sources for drug safety surveillance: computational framework and case studies","volume":"16","author":"Koutkias","year":"2017","journal-title":"Expert Opin. Drug Saf."},{"issue":"1","key":"10.1016\/j.schres.2018.03.006_bb0180","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1744-859X-4-10","article-title":"N-terminal fragment of B-type natriuretic peptide (NT-proBNP), a marker of cardiac safety during antipsychotic treatment","volume":"4","author":"Kropp","year":"2005","journal-title":"Ann. General Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2018.03.006_bb0185","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJM200107193450317","article-title":"Myocarditis and cardiomyopathy associated with clozapine use in the United States","volume":"345","author":"La Grenade","year":"2001","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.schres.2018.03.006_bb0190","doi-asserted-by":"crossref","first-page":"190","DOI":"10.5694\/j.1326-5377.2009.tb02345.x","article-title":"Clozapine-induced cardiotoxicity: a clinical update","volume":"190","author":"Layland","year":"2009","journal-title":"Med. J. Aust."},{"issue":"8","key":"10.1016\/j.schres.2018.03.006_bb0195","doi-asserted-by":"crossref","first-page":"e445","DOI":"10.1016\/S1470-2045(17)30535-1","article-title":"Cardiotoxic effects of anthracycline-based therapy: what is the evidence and what are the potential harms?","volume":"18","author":"Levis","year":"2017","journal-title":"Lancet Oncol."},{"issue":"2\u20133","key":"10.1016\/j.schres.2018.03.006_bb0200","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.schres.2011.10.014","article-title":"When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature","volume":"134","author":"Manu","year":"2012","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.schres.2018.03.006_bb0205","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1176\/appi.ajp.161.8.1334","article-title":"Physical health monitoring of patients with schizophrenia","volume":"161","author":"Marder","year":"2004","journal-title":"Am. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2018.03.006_bb0210","doi-asserted-by":"crossref","first-page":"134","DOI":"10.3371\/CSRP.6.3.5","article-title":"Clozapine: balancing safety with superior antipsychotic efficacy","volume":"6","author":"Meltzer","year":"2012","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"issue":"1","key":"10.1016\/j.schres.2018.03.006_bb0215","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/01.jcp.0000150217.51433.9f","article-title":"Adverse cardiac effects associated with clozapine","volume":"25","author":"Merrill","year":"2005","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2018.03.006_bb0220","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2125.2009.03596.x","article-title":"Drugs and dilated cardiomyopathies: a case\/noncase study in the French Pharmaco Vigilance Database","volume":"69","author":"Montastruc","year":"2010","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"3","key":"10.1016\/j.schres.2018.03.006_bb0225","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1177\/1039856213475684","article-title":"Echocardiographic monitoring for clozapine cardiac toxicity: lessons from real-world experience","volume":"21","author":"Murch","year":"2013","journal-title":"Australas. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2018.03.006_bb0230","doi-asserted-by":"crossref","first-page":"86","DOI":"10.5694\/mja11.11394","article-title":"Echocardiographic monitoring for clozapine-associated cardiac toxicity: time for review?","volume":"198","author":"Murch","year":"2013","journal-title":"Med. J. Aust."},{"issue":"6","key":"10.1016\/j.schres.2018.03.006_bb0235","doi-asserted-by":"crossref","first-page":"603","DOI":"10.4088\/JCP.12r08064","article-title":"Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided?","volume":"74","author":"Nielsen","year":"2013","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.schres.2018.03.006_bb0240","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1600-0447.2011.01776.x","article-title":"Reason for clozapine cessation","volume":"125","author":"Pai","year":"2012","journal-title":"Acta Psychiatr. Scand."},{"issue":"2","key":"10.1016\/j.schres.2018.03.006_bb0245","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/01.IDT.0000343814.12380.d4","article-title":"Optimizing clozapine treatment: part II","volume":"44","author":"Phansalkar","year":"2009","journal-title":"Psychopharm. Rev."},{"key":"10.1016\/j.schres.2018.03.006_bb0250","article-title":"Brain natriuretic peptide as a biomarker of asymptomatic clozapine-related heart dysfunction: a criterion for a more cautious administration","author":"Prisco","year":"2016","journal-title":"Clin. Schizophr. Relat. Psychoses"},{"issue":"3","key":"10.1016\/j.schres.2018.03.006_bb0255","doi-asserted-by":"crossref","first-page":"163","DOI":"10.2174\/1574886309666140428115040","article-title":"Clozapine safety, 40years later","volume":"9","author":"Raja","year":"2014","journal-title":"Curr. Drug Saf."},{"issue":"11\u221212","key":"10.1016\/j.schres.2018.03.006_bb0260","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1080\/j.1440-1614.2004.01481.x","article-title":"Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service","volume":"38","author":"Reinders","year":"2004","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2018.03.006_bb0265","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00213-012-2922-7","article-title":"Clozapine and therapeutic drug monitoring: is there sufficient evidence for an upper threshold?","volume":"225","author":"Remington","year":"2013","journal-title":"Psychopharmacology"},{"issue":"9","key":"10.1016\/j.schres.2018.03.006_bb0270","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/14740338.2016.1191468","article-title":"Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use","volume":"15","author":"Remington","year":"2016","journal-title":"Expert Opin. Drug Saf."},{"issue":"1\u20133","key":"10.1016\/j.schres.2018.03.006_bb0275","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.schres.2012.06.020","article-title":"Immunomodulatory effects of clozapine and their clinical implications: what have we learned so far?","volume":"140","author":"Roge","year":"2012","journal-title":"Schizophr. Res."},{"issue":"8","key":"10.1016\/j.schres.2018.03.006_bb0280","doi-asserted-by":"crossref","first-page":"976","DOI":"10.4088\/JCP.09m05024yel","article-title":"Diagnostic characteristics of clozapine-induced myocarditis identified by an analysis of 38 cases and 47 controls","volume":"71","author":"Ronaldson","year":"2010","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2018.03.006_bb0285","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/00048674.2011.572852","article-title":"A new monitoring protocol for clozapine-induced myocarditis based on an analysis of 75 cases and 94 controls","volume":"45","author":"Ronaldson","year":"2011","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"1\u20133","key":"10.1016\/j.schres.2018.03.006_bb0290","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.schres.2011.01.017","article-title":"Clinical course and analysis of ten fatal cases of clozapine-induced myocarditis and comparison with 66 surviving cases","volume":"128","author":"Ronaldson","year":"2011","journal-title":"Schizophr. Res."},{"issue":"10","key":"10.1016\/j.schres.2018.03.006_bb0295","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1177\/0004867412449299","article-title":"Clozapine-induced myocarditis and baseline echocardiography","volume":"46","author":"Ronaldson","year":"2012","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"2\u20133","key":"10.1016\/j.schres.2018.03.006_bb0300","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.schres.2012.08.018","article-title":"Rapid clozapine dose titration and concomitant sodium valproate increase the risk of myocarditis with clozapine: a case-control study","volume":"141","author":"Ronaldson","year":"2012","journal-title":"Schizophr. Res."},{"issue":"4","key":"10.1016\/j.schres.2018.03.006_bb0305","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1111\/acps.12416","article-title":"Clozapine-induced myocarditis, a widely overlooked adverse reaction","volume":"132","author":"Ronaldson","year":"2015","journal-title":"Acta Psychiatr. Scand."},{"issue":"5","key":"10.1016\/j.schres.2018.03.006_bb0310","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1177\/0004867414566871","article-title":"Evolution of troponin, C-reactive protein and eosinophil count with the onset of clozapine-induced myocarditis","volume":"49","author":"Ronaldson","year":"2015","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2018.03.006_bb0315","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1097\/JCP.0b013e318234ee66","article-title":"Usefulness of NT-pro-BNP and echocardiography in the diagnosis of subclinical clozapine-related cardiotoxicity","volume":"31","author":"Rostagno","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.schres.2018.03.006_bb0320","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2174\/157340011797183148","article-title":"Cardio-vascular risks associated with clozapine treatment","volume":"7","author":"Rostagno","year":"2011","journal-title":"Curr. Psychiatr. Rev."},{"issue":"2","key":"10.1016\/j.schres.2018.03.006_bb0325","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2174\/187152512800388876","article-title":"Does a subclinical cardiotoxic effect of clozapine exist? Results from a follow-up pilot study","volume":"10","author":"Rostagno","year":"2012","journal-title":"Cardiovasc. Hematol. Agents Med. Chem."},{"issue":"9817","key":"10.1016\/j.schres.2018.03.006_bb0330","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S0140-6736(11)60648-X","article-title":"Myocarditis","volume":"379","author":"Sagar","year":"2012","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.schres.2018.03.006_bb0335","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/0004867413502089","article-title":"Safety of long-term clozapine administration: frequency of cardiomyopathy and hyponatraemia: two cross-sectional, naturalistic studies","volume":"48","author":"Serrano","year":"2014","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"6","key":"10.1016\/j.schres.2018.03.006_bb0340","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1177\/1039856214553314","article-title":"Asymptomatic myocarditis during clozapine re-titration, in a patient who had previously been stable on clozapine for 10years","volume":"22","author":"Smith","year":"2014","journal-title":"Australas. Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2018.03.006_bb0345","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1176\/appi.ps.201300180","article-title":"Geographic and clinical variation in clozapine use in the United States","volume":"65","author":"Stroup","year":"2014","journal-title":"Psychiatr. Serv."},{"issue":"1","key":"10.1016\/j.schres.2018.03.006_bb0350","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/j.1440-1614.2006.01748_1.x","article-title":"Clozapine and heart in the Hunter region","volume":"40","author":"Tirupati","year":"2006","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"3","key":"10.1016\/j.schres.2018.03.006_bb0355","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1046\/j.1365-2125.2003.01773.x","article-title":"Low blood selenium concentrations in schizophrenic patients on clozapine","volume":"55","author":"Vaddadi","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"9206","key":"10.1016\/j.schres.2018.03.006_bb0360","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0140-6736(05)72452-1","article-title":"Clozapine and sudden death","volume":"355","author":"Warner","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.schres.2018.03.006_bb0365","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-244X-14-102","article-title":"Clozapine: a review of clinical practice guidelines and prescribing trends","volume":"14","author":"Warnez","year":"2014","journal-title":"BMC Psychiatry"},{"issue":"2","key":"10.1016\/j.schres.2018.03.006_bb0370","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1089\/1044546041648977","article-title":"Chart review for potential features of myocarditis, pericarditis, and cardiomyopathy in children and adolescents treated with clozapine","volume":"14","author":"Wehmeier","year":"2004","journal-title":"J. Child Adolesc. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.schres.2018.03.006_bb0375","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1365-2710.2004.00616_1.x","article-title":"Myocarditis, pericarditis and cardiomyopathy in patients treated with clozapine","volume":"30","author":"Wehmeier","year":"2005","journal-title":"J. Clin. Pharm. Ther."},{"issue":"2","key":"10.1016\/j.schres.2018.03.006_bb0380","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1177\/0004867414554269","article-title":"Clozapine-induced myocarditis: separating the wheat from the chaff","volume":"49","author":"Winckel","year":"2015","journal-title":"Aust. N. Z. J. Psychiatry"},{"issue":"9","key":"10.1016\/j.schres.2018.03.006_bb0385","first-page":"1185","article-title":"Antipsychotic clozapine (Clozaril): myocarditis and cardiovascular toxicity","volume":"166","author":"Wooltorton","year":"2002","journal-title":"CMAJ"},{"issue":"2","key":"10.1016\/j.schres.2018.03.006_bb0390","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1177\/1039856215604480","article-title":"Incidence and risk factors for clozapine-induced myocarditis and cardiomyopathy at a regional mental health service in Australia","volume":"24","author":"Youssef","year":"2016","journal-title":"Australas. Psychiatry"}],"container-title":["Schizophrenia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418301543?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920996418301543?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,29]],"date-time":"2020-10-29T08:36:06Z","timestamp":1603960566000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920996418301543"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":78,"alternative-id":["S0920996418301543"],"URL":"https:\/\/doi.org\/10.1016\/j.schres.2018.03.006","relation":{},"ISSN":["0920-9964"],"issn-type":[{"value":"0920-9964","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clozapine-induced cardiomyopathy and myocarditis monitoring: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Schizophrenia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.schres.2018.03.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}